Practical NeurologyOral Zunveyl Approved by FDA for Early Alzheimer Disease

Novel Oral Alzheimer’s Treatment Aims to Reduce GI Side Effects, Potentially Improving Patient Adherence

The FDA has approved Zunveyl (benzgalantamine), an oral therapy for mild-to-moderate Alzheimer’s disease (AD). Developed by Alpha Cognition, this prodrug of galantamine is designed to address common tolerability issues associated with acetylcholinesterase inhibitors. Zunveyl’s formulation aims to minimize gastrointestinal absorption, potentially reducing side effects and improving patient adherence.

Key Points:

• Zunveyl (benzgalantamine) is approved for mild-to-moderate Alzheimer’s disease
• It is a prodrug of galantamine, an acetylcholinesterase inhibitor (AChEI)
• Mechanism of action: Prevents breakdown of acetylcholine and enhances its release from presynaptic neurons
• Formulated to eliminate drug absorption in the gastrointestinal (GI) tract
• Aims to address common tolerability issues like GI side effects and insomnia
• Clinical studies showed bioequivalence to galantamine immediate-release tablets and extended-release capsules
• Minimal adverse events reported in clinical trials
• Will be available by prescription in US pharmacies starting Q1 2025
• Developed by Alpha Cognition, based in Vancouver, British Columbia, Canada

“This advancement marks a meaningful step forward in improving the quality of life for those living with Alzheimer’s and their families. As a geriatric psychiatrist specializing in Alzheimer disease, I am eager to incorporate this new treatment into our practice and see the positive difference it will make.”
– Elaine Peskind, MD, Friends of Alzheimer’s Research Professor of Psychiatry at the University of Washington School of Medicine

More on Alzheimer’s/Dementia